Literature DB >> 22350800

Hyaluronan oligomers-HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma.

Gal Journo-Gershfeld1, Dana Kapp, Yosi Shamay, Jindřich Kopeček, Ayelet David.   

Abstract

PURPOSE: To evaluate the effect of the size of low molecular weight hyaluronan (LMW-HA) oligomers on the targeting ability of the HA-containing copolymers to the CD44-overexpressing cells for delivering Paclitaxel (PTX) to ovarian cancer.
METHODS: LMW-HA oligosaccharides of 4, 6, 8, 10, 12 and 14 sugar residues were attained by digestion of HMW-HA using hyaluronate lyase at different incubation times and then attached to FITC-labeled HPMA copolymer precursor. The binding and uptake of the HA-modified HPMA-copolymer into CD44-expressing cells was studied by flow cytometry and confocal microscopy. PTX was further attached to HPMA-copolymer precursor bearing HA oligosaccharide at the size of 34 monosaccharides, through an acid-sensitive hydrazone linker. The cytotoxicity of the polymer was tested using cell viability assay.
RESULTS: Polymer conjugates bearing HA oligomers at the size of 10 oligosaccharides and above (HA(10-14)) bind actively and profoundly to CD44-overexpressing ovarian cancer cells (SK-OV-3) and internalize to the greatest extent relative to HA-polymer conjugates of 8 oligomers and below (HA(4-8)). The HA-modified HPMA-copolymer PTX conjugate (P-(HA)(34)-PTX) exhibited 50-times higher cytotoxicity towards CD44-overexpressing cells relative to the control, non-targeted, HPMA-copolymer PTX conjugate (P-PTX).
CONCLUSIONS: P-(HA)(34)-PTX was significantly more toxic than the non-targeted P-PTX in cells expressing high levels of CD44.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350800     DOI: 10.1007/s11095-012-0672-1

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  40 in total

Review 1.  Microtubule-targeted anticancer agents and apoptosis.

Authors:  Kapil N Bhalla
Journal:  Oncogene       Date:  2003-12-08       Impact factor: 9.867

2.  HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro.

Authors:  V Omelyanenko; C Gentry; P Kopecková; J Kopecek
Journal:  Int J Cancer       Date:  1998-02-09       Impact factor: 7.396

3.  A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells.

Authors:  Y Luo; M R Ziebell; G D Prestwich
Journal:  Biomacromolecules       Date:  2000       Impact factor: 6.988

4.  Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes.

Authors:  B Ríhová; T Etrych; M Pechar; M Jelínková; M Stastný; O Hovorka; M Kovár; K Ulbrich
Journal:  J Control Release       Date:  2001-07-06       Impact factor: 9.776

5.  Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel.

Authors:  J M Meerum Terwogt; W W ten Bokkel Huinink; J H Schellens; M Schot; I A Mandjes; M G Zurlo; M Rocchetti; H Rosing; F J Koopman; J H Beijnen
Journal:  Anticancer Drugs       Date:  2001-04       Impact factor: 2.248

6.  HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release.

Authors:  Tomás Etrych; Milada Sírová; L Starovoytova; Blanka Ríhová; Karel Ulbrich
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

7.  Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells.

Authors:  R E Eliaz; F C Szoka
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

8.  Synthesis, characterization, and preliminary assessment of anti-Flt1 peptide-hyaluronate conjugate for the treatment of corneal neovascularization.

Authors:  Eun Ju Oh; Kitae Park; Jun-Sub Choi; Choun-Ki Joo; Sei Kwang Hahn
Journal:  Biomaterials       Date:  2009-07-31       Impact factor: 12.479

Review 9.  Secondary structures in hyaluronan solutions: chemical and biological implications.

Authors:  J E Scott
Journal:  Ciba Found Symp       Date:  1989

10.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors:  Y Matsumura; H Maeda
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

View more
  18 in total

1.  Complexation of cell-penetrating peptide-polymer conjugates with polyanions controls cells uptake of HPMA copolymers and anti-tumor activity.

Authors:  Yosi Shamay; Lina Shpirt; Gonen Ashkenasy; Ayelet David
Journal:  Pharm Res       Date:  2013-09-10       Impact factor: 4.200

Review 2.  Design of smart HPMA copolymer-based nanomedicines.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

3.  Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.

Authors:  Kathryn M Camacho; Sunny Kumar; Stefano Menegatti; Douglas R Vogus; Aaron C Anselmo; Samir Mitragotri
Journal:  J Control Release       Date:  2015-04-25       Impact factor: 9.776

4.  Multifunctional tumor-targeting nanocarriers based on hyaluronic acid-mediated and pH-sensitive properties for efficient delivery of docetaxel.

Authors:  Shuangshuang Song; Fen Chen; Huan Qi; Fei Li; Tiegang Xin; Jingwen Xu; Tiantian Ye; Naicheng Sheng; Xinggang Yang; Weisan Pan
Journal:  Pharm Res       Date:  2013-10-24       Impact factor: 4.200

5.  Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel.

Authors:  Rui Zhang; Kui Luo; Jiyuan Yang; Monika Sima; Yongen Sun; Margit M Janát-Amsbury; Jindřich Kopeček
Journal:  J Control Release       Date:  2012-12-20       Impact factor: 9.776

6.  Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA.

Authors:  Zhenyu Shao; Jingyu Shao; Bingxu Tan; Shanghui Guan; Zhulong Liu; Zengjun Zhao; Fangfang He; Jian Zhao
Journal:  Int J Nanomedicine       Date:  2015-02-11

7.  β-casein nanovehicles for oral delivery of chemotherapeutic Drug combinations overcoming P-glycoprotein-mediated multidrug resistance in human gastric cancer cells.

Authors:  Maya Bar-Zeev; Yehuda G Assaraf; Yoav D Livney
Journal:  Oncotarget       Date:  2016-04-26

Review 8.  Targeting hyaluronic acid family for cancer chemoprevention and therapy.

Authors:  Vinata B Lokeshwar; Summan Mirza; Andre Jordan
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

9.  Hyaluronic acid conjugates for topical treatment of skin cancer lesions.

Authors:  Vinu Krishnan; Kevin Peng; Apoorva Sarode; Supriya Prakash; Zongmin Zhao; Sergey K Filippov; Kristina Todorova; Brittney R Sell; Omar Lujano; Shirin Bakre; Anusha Pusuluri; Douglas Vogus; Kenneth Y Tsai; Anna Mandinova; Samir Mitragotri
Journal:  Sci Adv       Date:  2021-06-11       Impact factor: 14.136

10.  Chemoenzymatic synthesis of oligohyaluronan-lipid conjugates.

Authors:  Dipali Ruhela; Saul Kivimäe; Francis C Szoka
Journal:  Bioconjug Chem       Date:  2014-03-28       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.